On July 22nd, Gelunhui reported that Tianjin Tianyao Pharmaceuticals (600488.SH), a subsidiary of Tianyao Pharmaceuticals, received a "Drug Supplement Approval Notice" issued by the National Medical Products Administration for the injection use of methylprednisolone sodium succinate (20mg) (referred to as "the drug" or "this product"), approving the consistency evaluation of the drug quality and efficacy with the generic drug.
Methylprednisolone sodium succinate for injection is a type of glucocorticoid drug primarily used for anti-inflammatory, immunosuppressive, treatment of blood diseases and tumors, treatment of shock, and other treatments.